Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1α,25 dihydroxyvitamin D3 treated Caco-2 cells

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 169-177

  Hou, Xiao Long ^a   Takahashi, Kyoko ^a   Kinoshita, Natsumi ^b   Qiu, Feng ^c   Tanaka, Ken ^d   Komatsu, Katsuko ^d   Takahashi, Koichi ^b   Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

C. longa; C. zedoaria; Caco 2; Curcumin; CYP3A4

Indexed keywords

CALCITRIOL; CURCUMA LONGA EXTRACT; CURCUMA ZEDOARIA EXTRACT; CURCUMIN; CYTOCHROME P450 3A4; MESSENGER RNA; METHANOL EXTRACTION RESIDUE;

ARTICLE; CATALYSIS; CELL STRAIN CACO 2; CONTROLLED STUDY; CURCUMA LONGA; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; METABOLISM; MOLECULAR MIMICRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE;

CACO-2 CELLS; CALCITRIOL; CELL SURVIVAL; CURCUMA; CURCUMIN; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; ENZYME INHIBITORS; HERB-DRUG INTERACTIONS; HUMANS; HYDROXYLATION; INHIBITORY CONCENTRATION 50; INTESTINAL MUCOSA; KETOCONAZOLE; NIFEDIPINE; OXIDATION-REDUCTION; PLANT EXTRACTS; RHIZOME; RIFAMPIN; RNA, MESSENGER; TESTOSTERONE;

EID: 34248588334     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.12.035     Document Type: Article

References (40)

1. Aiba T., Susa M., Fukumori S., and Hashimoto Y. The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180. Drug Metab. Pharmacokinet. 20 (2005) 268-274
2. Araujo C.C., and Leon L.L. Biological Activities of Curcuma L. Memórias do Instituto Oswaldo Cruz 96 (2001) 723-728
3. Bogaards J.J., Bertrand M., Jackson P., Oudshoorn M.J., Weaver R.J., Van Bladeren P.J., and Walther B. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30 (2000) 1131-1152
4. Cao H., Sasaki Y., Fushimi H., and Komatsu K. Molecular analysis of medicinally-used Chinese and Japanese Curcuma based on 18S rRNA gene and trnK gene sequences. Biol. Pharm. Bull. 24 (2001) 1389-1394
5. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J. Altern. Complement. Med. 9 (2003) 161-168
6. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai, Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., and Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001) 2895-2900
7. Cheng P.Y., Wang M., and Morgan E.T. Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. J. Pharmacol. Exp. Ther. 307 (2003) 1205-1212
8. Dresser G.K., and Bailey D.G. The effects of fruit juices on drug disposition: a new model for drug interaction. Eur. J. Clin. Invest. 33 (2003) 10-16
9. Evans A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther. Drug Monit. 22 (2000) 131-136
10. Firozi P.F., Aboobaker V.S., and Bhattacharya R.K. Action of curcumin on the cytochrome P450 system catalyzing the activation of aflatoxin B1. Chem. Biol. Interact. 100 (1996) 41-51
11. 3-modified Caco-2 cell monolyers. J. Pharmacol. Exp. Ther. 289 (1999) 1134-1142
12. Fugh-Berman A., and Ernst E. Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol. 52 (2001) 587-595
13. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf. 18 (1998) 251-272
14. Guengerich F.P. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem. Biol. Interact. 106 (1997) 161-182
15. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 1-17
16. Hara H., Yasunami Y., and Adachi T. Alteration of cellular phosphorylation state affects vitamin D receptor-mediated CYP3A4 mRNA induction in Caco-2 cells. Biochem. Biophys. Res. Commun. 296 (2002) 182-188
17. Hilgers A.R., Conradi R.A., and Burton P.S. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7 (1990) 902-910
18. Hu M., Li Y., Davitt C.M., Huang S.M., Thummel K., Penman B.W., and Crespi C.L. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm. Res. 16 (1999) 1352-1359
19. Kumashiro R., Hisamochi A., and Sata M. Liver injury by health food. SouGo RinSyou 55 (2006) 50-51
20. Lai E.Y., Chyau C.C., Mau J.L., Chen C.C., Lai Y.J., Shih C.F., and Lin L.L. Antimicrobial activity and cytotoxicity of the essential oil of Curcuma zedoaria. Am. J. Chin. Med. 32 (2004) 281-290
21. Lu C., and Li A.P. Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem. Biol. Interact. 134 (2001) 271-281
22. Maheshwari R.K., Singh A.K., Gaddipati J., and Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci. 78 (2006) 2081-2087
23. Matsuda H., Ninomiya K., Morikawa T., and Yoshikawa M. Inhibitory effect and action mechanism of sesquiterpenes from Zedoariae Rhizoma on d-galactosamine/lipopolysaccharide-induced liver injury. Bioorg. Med. Chem. Lett. 8 (1998) 339-344
24. Mills E., Montori V., Perri D., Phillips E., and Koren G. Natural health product-HIV drug interactions: a systematic review. Int. J. STD ATDS 16 (2005) 181-186
25. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr. Drug Metab. 7 (2006) 67-81
26. Neuhaus W., Bogner E., Wirth M., Trzeciak J., Lachmann B., Gabor F., and Noe C.R. A novel tool to characterize paracellular transport: the APTS-dextran ladder. Pharm. Res. 23 (2006) 1491-1501
27. Paine M.F., Criss A.B., and Watkins P.B. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J. Pharmacol. Exp. Ther. 312 (2005) 1151-1160
28. Ram A., Das M., and Ghosh B. Curcumin attenuates allergen-induced airway hyperresponsiveness in sensitized guinea pigs. Biol. Pharm. Bull. 26 (2003) 1021-1024
29. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 31 (2003) 533-539
30. Sasaki Y., Goto H., Tonda C., Hatanaka F., Shibahara N., Shimada Y., Terasawa K., and Komatsu K. Effects of Curcuma drugs on vasomotion in isolated rat aorta. Biol. Pharm. Bull. 26 (2003) 1135-1143
31. Schmiedlin-Ren P., Thummel K.E., Fisher J.M., Paine M.F., Lown K.S., and Watkins P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25-dihydroxyvitamin D3. Mol. Pharmacol. 51 (1997) 741-754
32. 3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab. Dispos. 29 (2001) 1446-1453
33. Sharma R.A., McLelland H.R., Hill K.A., Ireson C.R., Euden S.A., Manson M.M., Pirmohamed M., Marnett L.J., Gescher A.J., and Steward W.P. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7 (2001) 1894-1900
34. Syu W.J., Shen C.C., Don M.J., Ou J.C., Lee G.H., and Sun C.M. Cytotoxicity of curcuminoids and some novel compounds from Curcuma zedoaria. J. Nat. Prod. 61 (1998) 1531-1534
35. Thapliyal R., and Maru G.B. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem. Toxicol. 39 (2001) 541-547
36. Valentine S.P., Le Nedelec M.J., Menzies A.R., Scandlyn M.J., Goodin M.G., and Rosengren R.J. Curcumin modulates drug metabolizing enzymes in the female Swiss Webster mouse. Life Sci. 78 (2006) 2391-2398
37. Veronese M.L., Gillen L.P., Burke J.P., Dorval E.P., Hauck W.W., Pequignot E., Waldman S.A., and Greenberg H.E. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol. 43 (2003) 831-839
38. Waxman D.J. P450 gene induction by structurally diverse xenochemicals: centrtal role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369 (1999) 11-23
39. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., and Watkins P.B. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32 (2000) 339-361
40. Zhang L., Lin G., Chang Q., and Zuo Z. Role of intestinal first-pass metabolism of baicalein in its absorption process. Pharm. Res. 22 (2005) 1050-1058